TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML ...

in a poster presentation at the 66 th American Society of Hematology (ASH) Annual Meeting in San Diego. TUS+VEN+AZA triplet may establish a more effective, mutation agnostic standard of care for ...

The poster presentation will highlight recent partner study results showing immunogenicity improvement when delivered with the PharmaJet Stratis ® including: “PharmaJet Needle-free Systems ...

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc.

today announced the presentation of two posters at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting taking place December 8-11, 2024, in Phoenix, Arizona. The data ...

Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER ...

Jaguar Health (JAGX)family company Napo Pharmaceuticals provided an overview of the data from the poster presentation conducted yesterday, ...

All Environmental Studies majors participate in public poster presentations as part of the thesis process. A poster session is organized for Wednesday in the last week of the fall and winter semesters ...

The presentation will feature preclinical characterization of LAE118, a novel allosteric pan-mutant selective PI3Kα inhibitor. "We appreciate this recognition of our expertise and strength in ...

The abstract, selected for a poster presentation, is a Trials-in-Progress presentation of a Phase 1 investigator-initiated study of danvatirsen monotherapy followed by danvatirsen combination with ...